Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Opipramol→

Opipramol Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
315-72-0
Molecular formula
C23H29N3O
Molecular weight
363.5 g/mol
Drug class
Tricyclic-structure anxiolyticsigma-1 and sigma-2 receptor ligand
Mechanism of action
Unlike conventional tricyclic antidepressants, opipramol has relatively low monoamine-reuptake inhibition and acts predominantly through sigma-1 and sigma-2 receptor interactions, with additional affinity for histamine H1 and other central receptors. These effects modulate central anxiety and somatic symptom pathways.
Indications / reported uses
  • Treatment of generalised anxiety disorder and somatoform disorders in countries where opipramol is authorised.

Sources: https://pubmed.ncbi.nlm.nih.gov/?term=opipramol+sigma+receptor+mechanism · https://pubchem.ncbi.nlm.nih.gov/#query=opipramol · FDA product information

View request basketPrefer email? [email protected]
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Tricyclic-structure anxiolytic; sigma-1 and sigma-2 receptor ligand

Mechanism of action

Unlike conventional tricyclic antidepressants, opipramol has relatively low monoamine-reuptake inhibition and acts predominantly through sigma-1 and sigma-2 receptor interactions, with additional affinity for histamine H1 and other central receptors. These effects modulate central anxiety and somatic symptom pathways.

General use cases

  • Treatment of generalised anxiety disorder and somatoform disorders in countries where opipramol is authorised.

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

ERA assessment scope

Project-specific environmental risk assessment support

The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.

  • Phase I exposure screening and trigger evaluation.
  • Environmental fate and ecotoxicity review, with Phase II work where required.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
  • Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope

Environmental Risk Assessment (ERA)

ReguSight provides project-specific support for the Opipramol Environmental Risk Assessment (ERA) (the Opipramol ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.